GeoVax's CM04S1 COVID-19 Vaccine Shows Promising Results for Immunocompromised Patients

GeoVax Labs, Inc. will present at the Emerging Growth Conference on September 25, 2025, highlighting recent positive interim clinical results for GEO-CM04S1, the company's lead COVID-19 vaccine candidate. The presentation will feature data presented this month at two major international scientific meetings, demonstrating the vaccine's effectiveness in vulnerable patient populations.

Phase 2 data presented at the International Workshop on Chronic Lymphocytic Leukemia 2025 showed that CM04S1 achieved the study's immune response primary endpoint in chronic lymphocytic leukemia patients, while the comparator mRNA vaccine did not. Based on the Data Safety Monitoring Board recommendation, further enrollment is proceeding exclusively in the CM04S1 arm, indicating strong confidence in the vaccine's performance.

Interim results presented at the European Society of Clinical Microbiology and Infectious Disease 2025 demonstrated robust, durable T-cell and cross-variant antibody responses in immunocompromised blood cancer and post-transplant patients, with no serious adverse events reported. These findings reinforce CM04S1's differentiation versus standard-of-care vaccines and highlight its potential to address significant gaps in current COVID-19 protection strategies.

David Dodd, Chairman and CEO of GeoVax, stated that these results underscore the promise of CM04S1 as a multi-antigen solution for patients left behind by first-generation COVID-19 vaccines. The company's MVA platform is demonstrating the potential to deliver broad, durable immune protection where it is needed most, particularly for immunocompromised individuals who remain vulnerable despite existing vaccination options.

The clinical progress of CM04S1 represents an important advancement in COVID-19 vaccine development, specifically targeting populations that have shown inadequate response to current mRNA vaccines. This development matters because immunocompromised patients face significantly higher risks of severe COVID-19 outcomes and have limited effective prevention options. The demonstration of superior immune responses in these vulnerable groups could lead to better protection against COVID-19 for millions of immunocompromised individuals worldwide.

Participants may submit questions in advance to [email protected] or ask them live during the presentation. A replay will be made available following the event on https://www.EmergingGrowth.com and the Emerging Growth YouTube channel at https://www.youtube.com/EmergingGrowthConference.